ImmunityBio, Inc. (IBRX)
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs
ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter runway, though net debt remains high at $603 million. The company's robust adoption underpins current valuation; future growth hinges on expanding indications and successful clinical trial readouts.
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outlook, near-term risks include ongoing losses, potential dilution, regulatory hurdles, and manufacturing dependencies.
ImmunityBio: A Small Bet Is Warranted
ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK program and expanding pipeline support the investment thesis for IBRX.
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
Recent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could open significant new markets beyond bladder cancer. Major risks remain: FDA's RTF for sBLA and ImmunityBio's concerning cash position increase the likelihood of dilution.
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% upside, but this is far from guaranteed. The company's lymphopenia treatment would face zero competition and would provide a larger addressable market.
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA
ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX shares to around $2.00, but the trading volume was not extremely high. Despite the setback, I maintain a conviction level of 3 out of 5 for IBRX, focusing on potential long-term gains and upcoming catalysts.
